Skip to main content
Top
Published in: Clinical Rheumatology 4/2020

01-04-2020 | Gout | Brief Report

Recent updates on worldwide gout epidemiology

Authors: Camilla Mattiuzzi, Giuseppe Lippi

Published in: Clinical Rheumatology | Issue 4/2020

Login to get access

Abstract

To provide recent statistics on worldwide gout epidemiology. Current and prediction data on gout epidemiology were retrieved from the Global Health Data Exchange (GHDx) registry and from the World Health Organization (WHO) database on projected mortality. Overall, 7.44 million cases of gout have been estimated around the world in 2017 (incidence, 0.097%), with a prevalence of 41.22 million cases (0.54%), and causing 1.28 million DALYs (0.051% of all DALYs). Gout incidence, prevalence, and health loss considerably increased during the last 25 years and are all higher in men than in women. The burden of gout increases linearly with aging, until the age of 64 years, and is correlated with socio-demographic index (SDI), with incident risk of gout > 3-fold higher in high than in low SDI regions. Projections suggest that gout mortality may increase by 55% in 2060. The epidemiologic burden of gout remains high around the world, especially in men and in high SDI countries, with a trend that is unlikely to reverse soon.
Key Points
• A significant association can be found between gout and socioeconomic status.
• Projections suggest that gout mortality may increase by 55% in 2060.
• The epidemiologic burden of gout remains high around the world.
Literature
1.
go back to reference Fischer A, Cloutier M, Goodfield J, Borrelli R, Marvin D, Dziarmaga A (2017) The direct economic burden of gout in an elderly Canadian population. J Rheumatol 44:95–101CrossRef Fischer A, Cloutier M, Goodfield J, Borrelli R, Marvin D, Dziarmaga A (2017) The direct economic burden of gout in an elderly Canadian population. J Rheumatol 44:95–101CrossRef
2.
go back to reference Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ Jr, Crowson CS, Matteson EL, Bongartz T (2018) The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol 45:574–579CrossRef Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ Jr, Crowson CS, Matteson EL, Bongartz T (2018) The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol 45:574–579CrossRef
3.
go back to reference Cea Soriano L, Rothenbacher D, Choi HK, García Rodríguez LA (2011) Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 13:R39CrossRef Cea Soriano L, Rothenbacher D, Choi HK, García Rodríguez LA (2011) Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 13:R39CrossRef
4.
go back to reference Pisaniello HL, Lester S, Gonzalez-Chica D, Stocks N, Longo M, Sharplin GR, Dal Grande E, Gill TK, Whittle SL, Hill CL (2018) Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study. Arthritis Res Ther 20:143CrossRef Pisaniello HL, Lester S, Gonzalez-Chica D, Stocks N, Longo M, Sharplin GR, Dal Grande E, Gill TK, Whittle SL, Hill CL (2018) Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study. Arthritis Res Ther 20:143CrossRef
5.
go back to reference Roddy E, Choi HK (2014) Epidemiology of gout. Rheum Dis Clin N Am 40:155–175CrossRef Roddy E, Choi HK (2014) Epidemiology of gout. Rheum Dis Clin N Am 40:155–175CrossRef
6.
go back to reference Kuo CF, Grainge MJ, Zhang W, Doherty M (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11:649–662CrossRef Kuo CF, Grainge MJ, Zhang W, Doherty M (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11:649–662CrossRef
7.
go back to reference Pascart T, Lioté F (2019) Gout: state of the art after a decade of developments. Rheumatology (Oxford) 58:27–44CrossRef Pascart T, Lioté F (2019) Gout: state of the art after a decade of developments. Rheumatology (Oxford) 58:27–44CrossRef
10.
go back to reference GBD (2017) Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789–1858 GBD (2017) Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789–1858
12.
go back to reference Golenbiewski J, Keenan RT (2019) Moving the needle: improving the care of the gout patient. Rheumatol Ther 6:179–193CrossRef Golenbiewski J, Keenan RT (2019) Moving the needle: improving the care of the gout patient. Rheumatol Ther 6:179–193CrossRef
Metadata
Title
Recent updates on worldwide gout epidemiology
Authors
Camilla Mattiuzzi
Giuseppe Lippi
Publication date
01-04-2020
Publisher
Springer London
Keyword
Gout
Published in
Clinical Rheumatology / Issue 4/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04868-9

Other articles of this Issue 4/2020

Clinical Rheumatology 4/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine